Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier

AIDS

Volumn 15, Issue 4, 2001, Pages 483-491

  Van der Sandt, Inez C J ^a   Vos, Catherine M P ^a   Nabulsi, Lobna ^a   Blom Roosemalen, Margret C M ^a   Voorwinden, Heleen H ^a   De Boer, Albertus G ^a   Breimer, Douwe D ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Blood brain barrier; Caco 2; HIV protease inhibitors; In vitro; LLC PK1; Multidrug resistance associated protein; P glycoprotein

Indexed keywords

AMPRENAVIR; GLYCOPROTEIN P; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN; PROBENECID; PROTEINASE INHIBITOR; RITONAVIR; VALSPODAR; VERAPAMIL; ZOSUQUIDAR;

ACTIVE TRANSPORT; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; DRUG TRANSPORT; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ASTROCYTES; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CACO-2 CELLS; CARBAMATES; CATTLE; CELL LINE, TRANSFORMED; CELLS, CULTURED; COCULTURE TECHNIQUES; CYCLOSPORINS; DIBENZOCYCLOHEPTENES; ENDOTHELIUM, VASCULAR; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LLC-PK1 CELLS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROBENECID; QUINOLINES; RATS; RATS, WISTAR; RITONAVIR; SULFONAMIDES; SWINE; VERAPAMIL;

EID: 0035831246     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200103090-00007     Document Type: Article

References (36)

1. Combination therapy for HIV: Towards long term control of disease progression
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The advanced HIV disease ritonavir study group
5. Early penetration of the blood-brain barrier by HIV
6. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature
7. The brain in AIDS: Central nervous system HIV-I infection and AIDS dementia complex
8. HIV-1-related central nervous system diseases
9. Presence of an inducible HOC-1 latent reservoir during highly active antiretroviral therapy
10. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents
11. ABC-transporters, from microorganisms to man
12. Expression fo the multidrug resistance gene product (P-glycoprotein) in human and tumour tissues
13. P-glycoprotein (MDR1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection
14. + patients
15. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
16. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers
17. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A
18. Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells
19. Establishment and characterisation of an in vitro model of the blood-brain barrier, comprised of co-cultured primary bovine brain capillary endothelial cells and newborn rat astrocytes
20. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines
21. The reversal of multidrug resistance
22. Modulators of multidrug resistance
23. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979
24. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than cyclosporine analog SDZ PSC 833
25. 3H]-verapamil radioligand-binding assay
26. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein
27. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone -evidence for a third drug-binding site
28. The steady-plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals
29. Pharmacokinetics interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir
30. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir
31. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes
32. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effects of transport inhibitors
33. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system
34. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers
35. Astrocytes increase the functional expression of P-glycoprotein in an in vitro model of the blood-brain barrier
36. CNS as a sanctuary for HIV1 infection despite treatment with zidovudine, lamivudine and indinavir